Santhera starts European Phase III Study with its Lead Compound SNT-MC17 (idebenone) in Friedreich's Ataxia

December 15, 2005 02:00 ET | Source: Santhera Pharmaceuticals Holding AG Santhera Pharmaceuticals Holding AG